Advertisement
IVF vs VNDA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IVF is a Hold and VNDA is a Hold.
Momentum Indicator for IVF turns negative, indicating new downward trend
IVF saw its Momentum Indicator move below the 0 level on September 24, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In 76 of the 81 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for IVF turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 41 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IVF entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVF advanced for three days, in 157 of 191 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
IVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.084) is normal, around the industry mean (2.874). P/E Ratio (0.000) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.130) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. IVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
VNDA's RSI Oscillator is remaining in oversold zone for 8 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where VNDA advanced for three days, in 156 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
VNDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNDA as a result. In 72 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for VNDA turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 35 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for VNDA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.112) is normal, around the industry mean (2.973). P/E Ratio (-0.873) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.378) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. VNDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IVF | VNDA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 95 | 82 | |
P/E GROWTH RATING 1..100 | 96 | 18 | |
SEASONALITY SCORE 1..100 | n/a | 28 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IVF's Valuation (48) in the null industry is in the same range as VNDA (53) in the Biotechnology industry. This means that IVF’s stock grew similarly to VNDA’s over the last 12 months.
IVF's Profit vs Risk Rating (100) in the null industry is in the same range as VNDA (100) in the Biotechnology industry. This means that IVF’s stock grew similarly to VNDA’s over the last 12 months.
VNDA's SMR Rating (98) in the Biotechnology industry is in the same range as IVF (100) in the null industry. This means that VNDA’s stock grew similarly to IVF’s over the last 12 months.
VNDA's Price Growth Rating (82) in the Biotechnology industry is in the same range as IVF (95) in the null industry. This means that VNDA’s stock grew similarly to IVF’s over the last 12 months.
VNDA's P/E Growth Rating (18) in the Biotechnology industry is significantly better than the same rating for IVF (96) in the null industry. This means that VNDA’s stock grew significantly faster than IVF’s over the last 12 months.
| IVF | VNDA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | 1 day ago 81% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 73% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 75% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 76% |
| Advances ODDS (%) | 3 days ago 82% | 3 days ago 65% |
| Declines ODDS (%) | 1 day ago 90% | 9 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 82% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IVF’s FA Score shows that 0 FA rating(s) are green while VNDA’s FA Score has 1 green FA rating(s).
- IVF’s FA Score: 0 green, 5 red.
- VNDA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IVF’s TA Score shows that 4 TA indicator(s) are bullish while VNDA’s TA Score has 4 bullish TA indicator(s).
- IVF’s TA Score: 4 bullish, 4 bearish.
- VNDA’s TA Score: 4 bullish, 4 bearish.
Price Growth
IVF (@Medical/Nursing Services) experienced а -8.24% price change this week, while VNDA (@Biotechnology) price change was -4.48% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
IVF is expected to report earnings on Nov 16, 2026.
VNDA is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ETHO | 80.61 | -0.05 | -0.06% |
| Amplify Etho Climate Leadership U.S. ETF (ETHO) | |||
| ATMP | 35.32 | -0.20 | -0.56% |
| Barclays ETN+ Select MLP ETN (ATMP) | |||
| IDV | 42.32 | -0.25 | -0.59% |
| iShares International Select Dividend ETF (IDV) | |||
| CDIG | 25.30 | -0.41 | -1.59% |
| City Different Investments Global Equity ETF (CDIG) | |||
| LUNL | 1.66 | -0.16 | -9.02% |
| Defiance Daily Target 2X Long LUNR ETF | |||